{"id":"W2701201582","doi":"10.1358/dot.2017.53.5.2613690","title":"Brodalumab: The first anti-IL-17 receptor agent for psoriasis","year":2017,"lang":"en","type":"review","venue":"Drugs of today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Secukinumab; Ixekizumab; Psoriasis Area and Severity Index; Psoriasis; Ustekinumab; Psoriatic arthritis; Dermatology; Interleukin 17; Clinical trial; Erythroderma; Immunology; Internal medicine; Adalimumab; Immune system; Disease","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000777735,0.0006085074,0.002158101,0.0001497906,0.0007130123,0.00003962417,0.001321061,0.0008230534,0.0005078084],"category_scores_gemma":[0.000210491,0.0003722766,0.001582914,0.00009446677,0.000286202,0.00006739952,0.000198735,0.0002656854,0.0008548526],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009324025,"about_ca_system_score_gemma":0.0002061436,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007704298,"about_ca_topic_score_gemma":0.00002427589,"domain_scores_codex":[0.9977806,0.0002866056,0.0007594603,0.0005891463,0.00006749624,0.0005167152],"domain_scores_gemma":[0.9964186,0.0009035116,0.001116674,0.001430285,0.0001048227,0.00002613255],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003475301,0.0001133031,0.000006157216,0.002277375,0.001640377,0.000001067894,0.0001970491,1.155853e-7,0.00001040716,0.0001152606,0.1268715,0.8687326],"study_design_scores_gemma":[0.0008680641,0.0001056996,0.00001393731,0.0026928,0.002708789,0.00001232394,0.00003640499,4.92285e-8,0.0003009151,0.000019578,0.9928656,0.0003758614],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003875471,0.9893664,0.0000093234,0.000310532,0.004518044,0.001666115,0.002116552,0.0000508666,0.001923483],"genre_scores_gemma":[0.00006155168,0.978457,0.00008611505,0.00005490518,0.0003625709,0.0005987535,0.00129038,0.00007357537,0.01901514],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8683568,"threshold_uncertainty_score":0.9999231,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06135471088143997,"score_gpt":0.3181274239703031,"score_spread":0.2567727130888632,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}